Current Controlled Trials in Cardiovascular Medicine (Nov 2002)

Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone

  • Leenen Frans HH,
  • Williamson Jeff D,
  • Wright Jackson T,
  • Cushman William C,
  • Cutler Jeffrey A,
  • Davis Barry R,
  • Piller Linda B,
  • Einhorn Paula T,
  • Randall Otelio S,
  • Golden John S,
  • Haywood L Julian

DOI
https://doi.org/10.1186/1468-6708-3-10
Journal volume & issue
Vol. 3, no. 1
p. 10

Abstract

Read online

Abstract Background The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is a randomized, double-blind, active-controlled trial designed to compare the rate of coronary heart disease events in high-risk hypertensive participants initially randomized to a diuretic (chlorthalidone) versus each of three alternative antihypertensive drugs: alpha-adrenergic blocker (doxazosin), ACE-inhibitor (lisinopril), and calcium-channel blocker (amlodipine). Combined cardiovascular disease risk was significantly increased in the doxazosin arm compared to the chlorthalidone arm (RR 1.25; 95% CI, 1.17–1.33; P P Methods and Results Baseline characteristics (age, race, sex, blood pressure) did not differ significantly between treatment groups (P P = 0.83). Conclusion Results of the validation process supported findings of increased heart failure in the ALLHAT doxazosin treatment arm compared to the chlorthalidone treatment arm.

Keywords